Preparation and Evaluation of Liposomes Co-Loaded with Doxorubicin, Phospholipase D Inhibitor 5-Fluoro-2-Indolyl Deschlorohalopemide (FIPI) and D-Alpha Tocopheryl Acid Succinate (α-TOS) for Anti-Metastasis

Maoyuan Song†, Jiaxing Wang‡, Jiongxi Lei, Guanhua Peng, Wenxi Zhang, Yuanyuan Zhang, Mengya Yin, Jiajia Li, Yajie Liu, Xiaomeng Wei, Xinru Li*, and Guiling Li*

Abstract
Tumor metastasis has become a key obstacle to cancer treatment, which causes high mortality. Nowadays, it involves multiple complex pathways, and conventional treatments are not effective due to fewer targets. The aims of the present study were to construct a novel liposome delivery system co-loading a specific PLD inhibitor 5-fluoro-2-indolylides-chlorohalopemide (FIPI) in combination with antitumor drug doxorubicin (DOX) and functional excipient D-alpha tocopheryl acid succinate (α-TOS) for anti-metastasis. In this study, the liposomes containing three components (DFT-Lip) with different physicochemical properties were successfully prepared by film dispersion method combined with pH-gradient method. Physicochemical parameters such as particles size, potential, encapsulation efficiency, stability, and release profiles were investigated. In vitro and in vivo anti-metastasis effectiveness against highly metastatic breast cancer MDA-MB-231 cell line was evaluated. The liposomes showed uniform particle size (approximately 119 nm), high drug encapsulation efficiency (> 90%), slow release characteristics and stability. In vitro anti-tumor cell metastasis study demonstrated DFT-Lip could greatly inhibit motility, migration and invasion of MDA-MB-231 cells compared to other liposomes, predicting a synergistic anti-tumor metastasis effect between FIPI with α-TOS in liposomes. In vivo anti-metastasis study showed that DFT-Lip prevented the initiation and the progression of metastasis of high metastatic breast cancer. These results suggested that the liposomes containing DOX, FIPI, and α-TOS might be a promising strategy for metastatic tumor therapy in clinics.

Keywords: FIPI, DOX, α-TOS, Liposomes, Anti-metastasis
Introduction
Metastasis, an important hallmark of malignant tumors [1], is defined as the spread of malignant cells from the primary tumor to one or more other discontiguous organs [2]. Although surgery, radiation therapy, and chemotherapy have been relatively successful in controlling the primary tumor, the cancer remained incurable if tumor metastasis occurred [3, 4]. Tumor metastasis, which usually predicted poor prognosis and inevitable death, remained a great challenge in the clinical treatment of cancer.

The key to the prevention, delay, and treatment of tumor metastasis is to understand its mechanisms. Many studies have focused on complex biochemical processes of metastasis during the past few decades. These researchers divided metastasis into a series of sequential and interrelated steps [5–7], each of which could block the formation of metastatic lesions by being inhibited [8]. The potential therapeutic targets included epithelial-mesenchymal transition (EMT) process [9], mesenchymal-epithelial transition (MET) process [10], cancer stem cells (CSCs) [11], circulating tumor cells (CTCs) [6], disseminated tumor cells (DTCs) [6], and cell mobility [12].

Phospholipase D (PLD) enzymes as important members of phospholipase superfamily are present in a broad range of organisms such as viruses, yeast, bacteria, animals, and plants [13, 14]. Mammalian cells encode two classic PLD isoforms, PLD1, and PLD2 [15]. Evaluated PLD activity, as well as expression, has been reported in a variety of cancers [16, 17]. Although exact pathways and mechanisms were still unclear, PLDs have been proposed to play multiple cell biological roles such as the formation of lamellipodia [18], migration [17], cellular movement [19], invasion, and metastasis [20] in cancer through several molecular mechanisms. Given the fact that PLD played a crucial role in the invasion and metastasis of tumor cells, it can be speculated that inhibition of phospholipase D contributed to anti-tumor metastasis.

Specific inhibitors of PLD have been developed in recent years. There are several PLD1 and PLD2 specific inhibitors available in the market, including specific PLD1 inhibitors [21] (VU0155069 and VU-0359595), PLD2 specific inhibitors [22] (Halopemide, NOPT, and VU-0364739), and specific inhibitors of both PLD1 and PLD2 [23] (ML-299, VU-0155056, and VU-0285655-1). Among these inhibitors, 5-fluoro-2-indolyldes-chlorohalopemide (FIPI) was obtained from MedChem Express Co., Ltd (Shanghai, China). Doxorubicin hydrochloride (DOX) and D- alpha-tocopheryl acid succinate (a-TOS) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Cholesterol (Chol) was supplied from Sigma-Aldrich (St. Louis, MO, USA). Egg phosphatidylcholine (EPC) was obtained from LIPOID GENE TECHNOLOGY LTD. (Beijing, China). 

Materials and Methods
Egg phosphatidylcholine (EPC) was obtained from LIPOID (Germany). Cholesterol (Chol) was supplied from Sigma-Aldrich (St. Louis, MO, USA). Doxorubicin hydrochloride (DOX) and D- alpha-tocopheryl acid succinate (α-TOS) were obtained from Dalian Meilun Biotech Co., Ltd (Liaoning, China). 5-fluoro-2-indolyldes-chlorohalopemide (FIPI) was obtained from MedChem Express Co., Ltd (Shanghai, China).

Cell Culture and Animals
The human breast cancer MDA-MB-231 cell line was purchased from the Institute of Basic Medical Science,
Chinese Academy of Medical Science (Beijing, China). Highly metastatic breast cancer MDA-MB-231 cell line that stably expressed luciferase (MDA-MB-231/Luc) was obtained from Peking University Medical and Healthy Analytical Center. Cells were maintained in Dulbecco’s modified Eagle’s medium (Macgene, Beijing, China) supplemented with 10% fetal bovine serum (FBS, Gibco, USA), 100 units/ml penicillin, and 100 μg/ml streptomycin at 37 °C in a humidified atmosphere with 5% CO₂.

The female BALB/c nude mice (initial weight of 16–18 g) were purchased from the Peking University Experimental Animal Center (Beijing, China) and kept under SPF condition. All experimental procedures were performed in accordance with guidelines approved by the Ethics Committee of Peking University.

Preparation of Liposomes
The liposome preparation was accomplished by film dispersion method and pH-gradient method [35]. Briefly, EPC, Chol, and α-TOS were co-dissolved in chloroform at a ratio of 20:5:2 (w/w/w) in a pear-shaped bottle and the solvent was evaporated completely by a rotary vacuum evaporator in a water bath at room temperature. The lipid film was hydrated with 300 mM citrate buffer (pH 2.50), which was shaken at 50 rpm for 3 min. The suspensions were subsequently sonicated with a probe sonicator for 15 min, and successively extruded for 3 times with a 0.22-μm polycarbonate membranes filter. Then, the liposomes were passed onto Sephadex G-25 gel column to exchange the outer aqueous solution for 10 mM PBS (pH 7.40), which exhibited a transmembrane pH-gradient following gel filtration. To encapsulate FIPI into the liposome, FIPI dissolved in 300 mM citrate buffer was added into outer aqueous solution of liposome, pH of which was gradually adjusted to 7.40 with 1.0 M NaOH solution [36]. The liposome was incubated at 40 °C for 15 min in a water bath with magnetic stirring to encapsulate FIPI, and further incubated for 15 min after DOX dissolved in water was added into the liposome. After being separated on Sephadex G-25 gel column to remove the uncapsulated drug, the multifunctional liposomes (DFT-lip) were prepared. TOS liposomes (TOS-lip), FIPI liposomes (FIPI-lip), DOX liposomes (DOX-lip), DOX plus FIPI liposomes (DF-lip), and DOX plus

![Structural formulas of 5-fluoro-2-indolyldes-chlorohalopemide (FIPI), D-α-tocopheryl acid succinate (α-TOS), and doxorubicin hydrochloride (DOX).](image-url)
TOS liposomes (DT-lip) were constructed using the same procedures by excluding the addition of DOX, FIPI, or α-TOS, respectively. Blank liposomes (Blank-lip) without α-TOS, FIPI, and DOX were prepared by film dispersion method as above.

**Characterization of Liposomes**
The particle size, polydispersity index (PDI), and zeta potential values of liposomes were determined using Malvern Zetasizer Nano-ZS (Malvern, UK). The entrapped concentrations of DOX, FIPI, and α-TOS were assayed by HPLC. Chromatographic conditions of DOX and FIPI was as follows: column, Agilent Eclipse Plms C18 column (5 μm, 4.6 × 250 mm); detection wavelength, 233 nm; column temperature, 25 °C; mobile phase, methanol, and sodium acetate buffer (30 mM, pH = 3.40) (55:45,v/v); flow rate, 1.0 ml/min. HPLC condition of α-TOS was as follows: column, Agilent Eclipse Plms C18 column (5 μm, 4.6 × 250 mm); measuring wavelength, 285 nm; column temperature, 25 °C; mobile phase, methanol, and acetic acid (500:3.2, v/v); flow rate, 1.0 ml/min. The drug encapsulation efficacy (EE) and drug-loading content (LC) were calculated according to the following equations, respectively:

\[
EE\% = \frac{\text{amount of drug encapsulated}}{\text{amount of drug used}} \times 100\%
\]

\[
LC\% = \frac{\text{amount of drug encapsulated} + \text{amount of lipid}}{\text{amount of lipid}} \times 100\%
\]

**In Vitro Release Behavior Study**
The release of DOX and FIPI from DFT-lip in vitro was investigated by a dialysis method. Briefly, 1 ml of DFT-lip was added into the dialysis bag (MWCO 8000–14000 Da), which was immersed in 20 ml of release medium (10 mM PBS, pH7.4, pH5.0) and oscillated in a shaker (100 rpm) at 37 °C [37]. At different time point as designated, aliquots (1 ml) were withdrawn from the dialysate and replaced with equal volume of fresh PBS. The release amount of drug was determined by HPLC.

**Stability of Liposomes**
The stability of DFT-lip at 4 °C and 25 °C was checked by Malvern Zetasizer Nano-ZS (Malvern, UK) [38]. The particle size and PDI of liposomes were measured after liposomes diluted with distilled water. The determination was conducted every three days during liposomes stored at 4 °C and 25 °C.

**Cellular Uptake**
The cellular uptake characteristics of different liposomes and free DOX were evaluated by flow cytometry. MDA-MB-231 cells were seeded into 12-well plates at a density of 2 × 10^5 cells/well and maintained for 24 h. Afterwards, the cells were exposed to medium without FBS (as control), DOX-lip, DFT-lip, and free DOX dissolved in PBS at a concentration of 5 μM DOX, respectively. After incubation for 4 h, the cells were washed, then treated with cold PBS, and resuspended in 500 μl cold PBS. The cells fluorescence was then detected using a flow cytometer (Becton Dickinson, USA). Each assay was repeated in triplicate.

**Cytotoxicity of Liposomes**
The cell viability was tested by sulforhodamine-B staining assay [39] to investigate the effect of liposomal cytotoxicity on MDA-MB-231 cells status in wound healing, cell migration, and cell invasion assay. MDA-MB-231 cells were seeded into 96-well plates at a density of 8000 cells/well and incubated at 37 °C for 24 h. The cells were then treated with blank DMEM (as control), Blank-lip, FIPI-lip, DF-lip, DT-lip, and DFT-lip at a concentration of 2 μM FIPI for 7 h and 24 h, respectively. The cell culture supernatant was decanted and 200 μl of cold 10% (w/v) TCA was gently added to each well. After incubation at 4 °C for 1 h, the plates were washed five times with slow-running tap water and allowed plated to air-dry at room temperature. Each well was added into 100 μl of 0.4% SRB (w/v) solution and stained for 20 min at room temperature. Then, the plates were quickly rinsed five times with 1% (v/v) acetic acid to remove unbound dye and dried at room temperature. Finally, 150 μl of 10 mM Tris base solution (pH10.5) was added to each well, which was shook on a gyration shaker for 30 min. The absorbance at 540 nm was measured by a microplate reader (Infinite F50, Tecan Group Ltd., Shanghai, China) and the viability of cells was calculated using the following formula:

\[
\text{cell viability(%) = } \frac{\text{absorbance at 540 nm for treated cells}}{\text{absorbance at 540 nm for control cells}} \times 100\%
\]

**Wound Healing Assay**
MDA-MB-231 cells were firstly seeded in a 6-well culture plate at a density of 4 × 10^5 cells/well and maintained in DMEM with 10% fetal bovine serum. After cells were grown to approximate 90% confluence, a scratch with constant width was done in monolayer of cells with a 200-μl pipette tip. The cells were washed twice with PBS to remove the suspended cells and further incubated for 48 h with blank DMEM (as control), Blank-lip, FIPI-lip, DF-lip, DT-lip, and DFT-lip at a concentration of 2 μM FIPI at 37 °C in a humidified atmosphere with 5% CO2, respectively. Wound closure was photographed at different time-points after scratch using a fluorescence microscope (Olympus, Japan).
Cell Migration Assay and Cell Invasion Assay
MDA-MB-231 cells were serum-starved for 2 h and then resuspended at a density of $1.0 \times 10^6$ cells/ml in serum-free DMEM. One hundred microliter of cell suspension were seeded into the upper chambers of transwell inserts (Corning, USA) that were separated from the lower wells by a 6.5-mm diameter and 8-mm-pore-size polycarbonate membrane [40]. The lower chambers were filled with 500 μl of DMEM with 10% FBS as a chemoattractant. Then, the cells were incubated with blank DMEM (as control) for 7 h, Blank-lip, FPI-lip, DF-lip, DT-lip, DFT-lip at a concentration of 2 μM FPI, at 37 °C in a humidified 5% CO2 cell culture incubator. After that, the cells on the upper side of the insert membrane were removed with cotton swabs. The cells on the lower side of the insert membrane were fixed with 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) and stained with 1% crystal violet in methanol/PBS (1:4, v/v), and viewed under a microscope (Olympus, Japan).

Cell invasion assay was carried out similar to cell migration assay described above in the transwell chambers coated with Matrigel layer except for incubation time of 24 h.

Prevention of Tumor Metastasis In Vivo and Safety Evaluation
To study the effects of liposomes on the prevention of tumor metastasis in vivo, an animal assay was performed following the method previously reported [41]. In brief, 200 μl of MDA-MB-231/Luc cell suspension at a density of $5 \times 10^6$ cells/ml was inoculated via the tail vein of the nude μ200 following the method previously reported [41]. In brief, tumor metastasis in vivo, an animal assay was performed.

Statistical Analysis
The results were expressed as mean ± standard deviation. The SPSS 13.0 software (Chicago, Illinois, USA) was applied in the statistical analysis. An unpaired, two-tailed Student's t test was used to determine the significance of the difference between two group means. Values of $p < 0.05$ meant statistically significant difference for all tests.

Results
Preparation and Characterization of Liposomes
Characterizations of the liposomes prepared were listed in Table 1. All of liposomes had an average particle size of about 84–120 nm with a narrow PDI ranged from 0.183 to 0.230, and were negatively charged. More specifically, the average diameter of liposomes containing one component, such as DOX, α-TOS, or FPI, increased slightly to 84–110 nm as compared to that of Blank-lip (88.58 ± 0.27 nm). Similarly, the liposome particle size, which encapsulated two of them, varied in the range of 102–108 nm. In contrast, the DFT-lip loading all three components had the largest particle size, 119.00 ± 0.80 nm. In addition, the EE of liposomes encapsulated one component was over 94%, which was not remarkably different with those that encapsulated two or more components. In summary, all of the liposomes with small particle size, uniform particle size distribution, negative charge, and high EE, were prepared by the definite prescription and process, and the difference in the characteristics between different liposomes was not obvious.

In Vitro Release
As shown in Fig. 2, the in vitro release percentage of DOX and FPI from the DFT-lip were below 2% within the initial 2 h at pH7.4 and pH5.0, indicating no burst release. Furthermore, the release of DOX and FPI from the liposomes at pH7.4 was below 20% for 48 h, which meant little leakage outside liposomes into blood circulation.

Shelf Stability of Liposomes
The shelf stability of DFT-lip at different temperature was assessed by Malvern Zetasizer Nano-ZS. As shown in the Fig. 3, particle size and PDI of DFT-lip stored at 4 °C for 15 days and stored at 25 °C for 9 days were not altered obviously, while the remarkable increase in size and PDI was displayed for DFT-lip stored at 25 °C for more than 9 days. These stability data demonstrated that DFT-lip were stable at 4 °C for 15 days and at 25 °C for 9 days to reach the tumor by EPR effect.

Cellular Uptake by MDA-MB-231 Cells
From the flow cytometry analysis result as shown in Fig. 4, free DOX exhibited the highest fluorescent intensity than
DOX-lip and DFT-lip ($p < 0.001$), indicating the highest cellular uptake. Compared to DOX-lip, the cellular uptake of DFT-lip was not significant ($p > 0.05$).

**Wound Healing, Cell Migration, and Invasion Assay**

As shown in Fig. 5, the viability of cells incubated at the same time and sample concentration as cell migration/invasion assay was above 90%, indicating that the inhibition ability on cell mobility, migration, and invasion was not caused by the cytotoxicity of the formulations. DOX, FPII, and α-TOS were completely encapsulated within liposomes thereby avoiding false-positive results caused by its cytotoxicity.

To investigate the effects of liposomes on cell motility, migration and invasion, wounding healing, cell migration, and invasion assays were conducted in MDA-MB-231 cells, respectively. As shown in Fig. 6a, the scratch in the control group was visibly healed after being incubated for 48 h, indicating excellent motility of MDA-MB-231 cells. Scratches in the Blank-lip and DT-lip group were invisible, while no obvious healing was observed in FPII-lip, DF-lip, and DFT-lip group. It demonstrated that Blank-lip and DT-lip showed no inhibition ability on MDA-MB-231 cell mobility, whereas FPII-lip, DF-lip, and DFT-lip could tremendously inhibit MDA-MB-231 cell mobility. Moreover, the result of the transwell migration and invasion assays also confirmed the effect of liposomes on cell migration inhibition. Cell migration and invasion assay were shown in Fig. 6b, c. There were more cells in the lower surface of the transwell chamber for the control, Blank-lip, and DT-lip group, indicating that liposomes without FPII took no effect on cell migration/invasion. By comparison, less cells migrated/invaded to the lower surface of the transwell chamber in the FPII-lip, DF-lip, and DFT-lip group, which illustrated that MDA-MB-231 cell migration or invasion was distinctly depressed by FPII-lip, DF-lip, and

### Table 1 Characterization of all liposomes

| Liposomes | Particle size (nm) | PDI | Zeta potential (mv) | Encapsulation efficiency (%) | Drug-loading content (%) |
|-----------|-------------------|-----|---------------------|-----------------------------|--------------------------|
|           |                   |     |                     | DOX | FPII | TOS | DOX | FPII | TOS |
| Blank-lip | 88.58 ± 0.27      | 0.230 ± 0.004 | −13.80 ± 0.66      | −   | −    | −   | −   | −    | −   |
| DOX-lip   | 84.53 ± 0.45      | 0.225 ± 0.005 | −27.07 ± 0.38      | 96.83 ± 1.30 | −    | −   | 1.33 ± 0.01 | −    | −    |
| FPII-lip  | 93.58 ± 0.43      | 0.220 ± 0.017 | −31.63 ± 0.40      | −   | 96.07 ± 1.85 | −   | −   | 8.76 ± 0.19 | −    | −    |
| TOS-lip   | 108.60 ± 0.75     | 0.187 ± 0.007 | −50.33 ± 1.61      | −   | −    | 94.10 ± 0.03 | −   | −    | 66.92 ± 0.67 |
| DF-lip    | 102.73 ± 1.16     | 0.243 ± 0.009 | −27.97 ± 0.67      | 96.28 ± 2.50 | 94.80 ± 1.27 | −   | 1.32 ± 0.03 | 8.86 ± 0.06 | −    | −    |
| DT-lip    | 108.40 ± 0.87     | 0.183 ± 0.016 | −59.40 ± 1.22      | 94.58 ± 2.87 | −    | 91.29 ± 2.84 | 1.19 ± 0.06 | −    | 65.67 ± 0.59 |
| DFT-lip   | 119.00 ± 0.80     | 0.188 ± 0.010 | −58.50 ± 1.04      | 93.45 ± 3.71 | 91.46 ± 3.71 | 91.42 ± 1.94 | 1.19 ± 0.04 | 8.69 ± 0.19 | 65.16 ± 0.18 |

All data presented here were calculated as the mean ± SD ($n = 3$) for three different preparations.

---

**Fig. 2** In vitro release profiles of FPII and DOX from DFT-lip

**Fig. 3** Stability of DFT-lip at 4 °C and 25 °C in PBS for 15 days determined by particle size and polydispersity index
DFT-lip. The results demonstrated that FIPI played a key factor in liposomal delivery system exerting anti-invasive and anti-migration.

**Prevention of Tumor Metastasis In Vivo**

As shown in Fig. 7a, the lung of normal nude mice was not fluorescent, while the nude mice injected with MDA-MB-231/Luc cells was fluorescent in the lung, demonstrating that the nude mice model of breast cancer metastasis was successfully constructed. As depicted in Fig. 7b, the lungs of nude mice in DFT-lip group showed weaker fluorescence than those in Blank-lip group, and two of nude mice in the DFT-lip group even did not exhibit fluorescence in the lung. The semi-quantitative result of fluorescence intensity as shown in Fig. 7c, there was a highly significant difference ($p < 0.001$) in the fluorescence intensities between the Blank-lip group and DFT-lip group. All data presented here indicated that DFT-lip could inhibit the progression and prevent the initiation of metastasis of highly metastatic breast cancer. In respect to the safety evaluation of liposomes in vivo, body weight monitoring of nude mice during treatment. As shown in Fig. 7d, the body weight of nude mice in each experimental group showed a similar trend that was an initially slight decrease and a subsequent rise. There was no significant difference ($p > 0.05$) among all the groups at different time points, indicating less systemic toxicity of Blank-lip and DFT-lip.

Besides, blood routine tests after treatment were conducted. Both Blank-lip and DFT-lip induced no significant changes ($p > 0.05$) in all blood routine results compared to the control group as listed in Table 2. In total, DFT-lip exhibited good safety profiles in vivo.

**Discussion**

Phospholipase D enzymes have long been proposed to play multiple cell biological roles in cancer progression, especially in metastasis [13, 14, 23]. Metastasis could be suppressed through inhibiting PLD activity by FIPI. In this study, multifunctional doxorubicin liposomes, containing FIPI, α-TOS, and DOX, were constructed for the inhibition of tumor metastasis.

At first, based on the different physicochemical properties of DOX, FIPI, and α-TOS, liposomes were prepared using film dispersion method, which encapsulated drug via pH-gradient method. α-TOS, a lipophilic, and amphiphilic ingredient was incorporated into the lipid bilayer when the lipid membrane was hydrated, while DOX and FIPI as weakly basic drugs penetrated the inner aqueous phase of liposomes through active pH-gradient encapsulation to achieve high drug loading. Since the transmembrane pH gradients ($\Delta$pH) strongly influenced the equilibrium transbilayer distribution of weak bases across lipid membranes, the pH of the extraliposomal phase was precisely adjusted.
to achieve high encapsulation efficacy [42]. In addition, only in a dissolved state can the drug be actively encapsulated into the liposomes in response to ΔpH. In preparation of liposome drug loading, FIPI had a predicted solubility (25 °C) below 0.093 g/L at pH7.4, but approximately 3.5 g/L at pH2–4, calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02, and was soluble in citrate buffer (pH2.5) but precipitated immediately in PBS (pH7.4) according to the pre-experimental results (data not shown). Therefore, the pH of the extra-liposomal phase should be lowered to dissolve sufficient FIPI and obtain the desired transmembrane loading of FIPI. However, this might induce the leakage of pre-encapsulated doxorubicin due to the decrease of the pH gradient. On the other hand, DOX powder or DOX aqueous solution could be directly added into the extraliposomal phase and be encapsulated into the liposomes without the decrease of ΔpH, which caused no leak of FIPI. Therefore, in order to achieve satisfactory co-encapsulation of FIPI with DOX, only FIPI was actively encapsulated firstly, following by DOX loading. The encapsulation efficiency of all the liposomes exceeded 94% as listed in Table 1, indicating that the above adjustment of liposomal preparation was reasonable and successful.

Except for high EE, the ideal liposomes should also demonstrate good characterizations of a low particle size, uniform size distribution, and a certain zeta potential. Among them, particle size is one of the most important parameters that determine the biological fate of carriers. Increased particle size reduces cell permeability [43] and cell uptake [44], alters tissue distribution characteristics [45], and is more easily recognized by the immune system to clear, thereby impairing passive targeting [46]. For the liposomes that encapsulated three ingredients (DOX, FIPI, and α-TOS), drug-loading process using a pH-gradient method caused a little increase in particle size to ~110 nm compared to that for the Blank liposomes, which tended to display high delivery efficiency and be accumulated into tumor tissues through permeability and retention (EPR) effect [47, 48]. The results demonstrated that the size of liposomes prepared using thin membrane together with pH-gradient method was not affected by more than two co-encapsulating drugs with different physicochemical properties. Zeta potential is another important parameter that influences the biological fate of particles that affected cellular adhesion/uptake and drug delivery [49]. Normally, liposomes with cationic lipids are prone to binding cells than liposomes with anionic lipids due to electrostatic interaction with negatively charged cell membrane (sialic acids and phospholipid head groups) [50]. DOX and FIPI with positive charge were encapsulated within the internal phase of the liposomes and therefore took no effect on the zeta potential of the liposomes. The carboxyl group of α-TOS located in the lipophilic interfacial region where it increased the membrane surface charge dissociated into negative ion at physiological pH, indicating that the zeta negative potential of the liposomes was further increased compared to that of the Blank liposomes. The enhanced
Fig. 7 In vivo anti-metastasis study of the liposomes. 

**a** Bioluminescent images of the nude mice model of lung metastasis of breast cancer, which was constructed with the injection of MDA-MB-231/Luc cells via tail vein. 

**b** Representative in vivo bioluminescent images of mice in a preventive protocol treated with Blank-lip and DFT-lip (n = 8).

**c** The extent of tumor metastasis burden was quantified (n = 8). Notes: ***p < 0.001 versus Blank-Lip.

**d** Body weight changes for the tumor-bearing mice.
electrostatic repulsion between particles helps to stabilize the liposomes during storage [51] and clinical application.

In the drug release study, pH5.0 and pH7.4 were used to simulate the physiological condition and endo-lysosomal environment of tumor cells. The release percentage of FPI and DOX from the liposomes was higher at pH5.0 than that at pH7.4 as shown in Fig. 2, respectively. The relatively quick drug release rate at pH5.0 might be attributed to increased solubility of weakly basic DOX and FPI in acidic release media. Therefore, after accumulated to tumor tissues via EPR effect and the liposomes were taken up by tumor cells via endocytosis and trapped in endosome. Its weakly acidic environment induced rapidly the release of drugs from liposomes in endosome to exhibit a therapeutic effect [47, 52].

It was generally believed that the uptake of drugs by cells was one of the key elements of efficacy. For the result that cellular uptake of liposomes loading doxorubicin was lower than free DOX, it was explained by the fact that free doxorubicin rapidly diffused into the cells [53], by contrast, liposomes enter the cell much slower by endocytosis. In our study, no significant difference was displayed in cellular uptake between DOX-lip and DFT-lip. This phenomenon was attributed to no obvious difference in particle size, zeta potential values, and no surface modification for different liposomes, due to the fact that particle size, zeta potential, and surface modification of nanoparticles influenced the cellular uptake [54–56]. The uptake results indicated that anti-invasion and migration effects might not be related to the uptake capacity of the liposomes.

According to the results of wounding healing, cell migration and invasion assay, only the liposomes encapsulated FPII apparently exhibited inhibitory effects on breast cancer MDA-MB-231 cell mobility, migration, and invasion, and DT-lip showed no inhibitory effects in cell invasion assay, which contradicted the report that α-TOS could inhibit tumor cell invasion [57]. Doxorubicin at a non-toxic concentration induced cell migration and cell invasion in highly metastatic breast cancer cells [58, 59], thereby α-TOS alone could not offset the above effect of DOX without FPII. More importantly, DFT-lip exhibited the strongest inhibitory effects among all the experimental groups, predicting a synergistic anti-metastatic effect between α-TOS and FPII on metastatic potential MDA-MB-231 cells. As already reported, α-TOS inhibited activity of NF-κB in cancer cell invasiveness associated with MMPs that were the key enzymes in the proteolysis of the basement membrane during invasion [57]. At the same time, PLD was downstream transcriptional target molecule of NF-κB; therefore, α-TOS might abolish PLD1 expression via inhibition of NF-κB transactivation [59], which assisted FPII in synergistic anti-metastatic efficacy as illustrated with Fig. 8.

The metastatic process, from a physical point of view [62], can be termed a series of steps such as detachment, intravasation, circulation, extravasation, colonization, and eventually reactivation [5]. Once inside the circulatory system, the tumor cells aggregated through interaction with platelets and fibrinogen, shielding the tumor cells from being recognized and cleared by the immune system, promoting EMT and eventually assisting them in seeding at distal metastatic sites [63, 64]. In the above process, the NF-κB pathway, required for induction and maintenance of EMT, was also essential for extravasation and metastatic seeding [65]. Besides, the interaction between tumor cells and platelets was impaired in mice lacking PLD1 [26]. Therefore, the result of tumor metastasis in vivo demonstrated that DFT-lip not only suppressed EMT through α-TOS-mediated inhibition of NF-κB, but also interfered tumor cell-platelet interaction via lower PLD expression/activity suppressed by FPII, preventing the initiation and progression of tumor metastasis.

### Table 2 Results of blood examination results from the retro-orbital sinus of mice after the administration of liposome formulations

| Assay | Control | Blank-lip | DFT-lip |
|-------|---------|-----------|---------|
| GR    | 7.30 ± 1.22 | 7.04 ± 1.29 | 6.21 ± 0.96 |
| GR%   | 13.61 ± 7.25 | 13.94 ± 0.96 | 13.74 ± 0.39 |
| HCT   | 16.28 ± 0.38 | 16.28 ± 0.34 | 15.84 ± 0.35 |
| MCH   | 16.32 ± 4.27 | 16.00 ± 4.87 | 16.25 ± 5.34 |
| MCHC  | 33.00 ± 9.21 | 32.71 ± 8.85 | 32.63 ± 6.21 |
| MCV   | 49.85 ± 1.11 | 49.76 ± 1.26 | 49.10 ± 1.22 |
| MO    | 0.94 ± 0.40 | 1.34 ± 0.43 | 1.09 ± 0.34 |
| MO%   | 12.99 ± 5.56 | 19.37 ± 5.54 | 17.16 ± 3.74 |
| MPV   | 5.31 ± 0.15 | 5.45 ± 0.21 | 5.51 ± 0.17 |
| PCT   | 0.24 ± 0.03 | 0.26 ± 0.02 | 0.23 ± 0.03 |
| PDL   | 13.61 ± 0.79 | 13.94 ± 0.96 | 13.74 ± 0.39 |
| PLT   | 451.25 ± 47.78 | 481.75 ± 32.47 | 491.38 ± 44.64 |
| RBC   | 10.04 ± 0.26 | 9.83 ± 0.42 | 9.85 ± 0.21 |
| RDM   | 14.25 ± 0.97 | 14.19 ± 0.66 | 14.73 ± 1.07 |
| WBC   | 7.30 ± 1.22 | 7.04 ± 1.29 | 6.21 ± 0.96 |

Data are presented as the mean ± SD (n = 8). GR, neutrophil granulocyte; HCT, hematocrit; HGB, hemoglobin; LY, lymphocyte; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; MCV, mean corpuscular volume; MO, intermediate cell; MPV, mean platelet volume; PCT, thrombocytopenia; PDL, platelet distribution width; PLT, platelet; RBC, red blood cells; RDM, red cell volume distribution width; WBC, white blood cells.
Conclusions

This study, for the first time, utilizes phospholipase D pathways to affect invasion, migration, or metastasis of tumor cells. Phospholipase D can promote tumor cell invasion and migration through multiple pathways. Therefore, inhibition of phospholipase D can obtain inhibitory effect from multiple pathways and is an efficient anti-invasion strategy.

In this study, three active ingredients (DOX, FIPI, and α-TOS) with different physicochemical properties were successfully co-loaded in liposomes that showed uniform particle size, high-encapsulation efficiency, negative charge, storage stability, and control release profiles to achieve co-delivery and ensure the efficacy of the three components as a promising anti-metastasis strategy.

Abbreviations

Chol: Cholesterol; CSCs: Cancer stem cells; CTCs: Circulating tumor cells; CXCR-4: Chemokine receptor type 4; DMEM: Dulbecco’s modified Eagle’s medium; DOX: Doxorubicin; DPBS: Dulbecco’s phosphate buffered saline;
DTCs: Disseminated tumor cells; EE: Encapsulation efficiency; EMT: Epithelial-mesenchymal transition; EPC: Egg phosphatidylcholine; FBS: Fetal bovine serum; FPI: 5-fluoro-2-indolyl-3-chlorohomophenol; GEF: Guanine nucleotide exchange factors; LC: Loading content; MET: Mesenchymal-epithelial transition; MMP: Matrix metalloproteinases; PA: Phosphatidic acid; PC: Phosphatidylcholine; PFA: Paraformaldehyde; PLD: Phospholipase D; SRB: Sulfurhydroamine; TCA: Trichloroacetic acid; TGFβ: Transforming growth factor beta; TβRII-Kl: Transforming growth factor beta type I receptor kinase inhibitors; α-TOS: D-α-tocopheryl acid succinate

Funding
This work was supported by CAMS Initiative for Innovative Medicine (2017-I2M-1-012) and the National Natural Science Foundation of China (No. 81541085).

Availability of Data and Materials
The datasets supporting the conclusions of this article are included within the article.

Authors’ Contributions
MS and JW were responsible for experimental design, research work, and results. JL guided in vitro anti-migration studies and in vivo anti-metastasis studies. Other authors analyzed the data and discussion. All authors read and approved the final manuscript.

Competing Interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 15 October 2018 Accepted: 1 April 2019
Published online: 18 April 2019

References
1. Norouzi S, Gorgi Valokala M, Mosaffa F, Zirak MR, Zamani P, Behravan J (2018) Crosstalk in cancer resistance and metastasis. Crit Rev Oncol Hematol 132:145–153
2. Li S, Li G (2014) Cancer stem cells and tumor metastasis (Review). Int J Oncol 44(6):1805–1812
3. Ahmad O, Chan M, Savage P, Watabe K, Lo HW, Qasem S (2016) Biology and treatment of metastasis of sarcoma to the brain. Front Biosci (Elite Ed) 8:233–244
4. Gao Y, Xie J, Chen H, Gu S, Zhao R, Sha J, Jia L (2014) Nanotechnology-based intelligent drug design for cancer metastasis treatment. Biotechnol Adv 32(6):761–777
5. Ganapathy V, Moghe PV, Roth CM (2015) Targeting tumor metastases: Drug delivery mechanisms and technologies. J Control Release 219:212–223
6. Sun Y, Ma L (2015) The emerging molecular machinery and therapeutic targets of metastasis. Trends Pharmacol Sci 36(6):349–359
7. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Science 334(6056):1659–1664
8. Fidler IJ, Kripke ML (2015) The challenge of targeting metastasis. Cancer Metastasis Rev 34(4):653–641
9. Davis FM, Stewart TA, Thompson EW, Monteith GR (2014) Targeting EMT in cancer: opportunities for pharmacological intervention. Trends Pharmacol Sci 35(9):479–488
10. Tsai JH, Yang J (2013) Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev 27(20):2192–2206
11. Shiozawa Y, Nie BA, Pienta KJ, Morgan TM, Talchman RS (2013) Cancer stem cells and their role in metastasis. Pharmacol Ther 138(2):285–293
12. Palmer TD, Ashby WJ, Lewis JD, Zijlstra A (2011) Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 63:588–581
13. Majdop S, Skomick Y, Avital S, Berkovich L (2018) Phospholipase D activation mediates growth and migration of colon cancer cells interacting with cancer-associated fibroblasts. Cell Mol Biol 64(14):84–88
14. Frohman MA (2015) The phospholipase D superfamily as therapeutic targets. Trends Pharmacol Sci 36(3):137–144
15. Cho JH, Han JS (2017) Phospholipase D and its essential role in cancer. Mol Cells 40(11):805–813
16. Gomez-Cambroner J, Carman GM (2014) Thematic minireview series on phospholipase D and cancer. J Biol Chem 289(33):22545–22556
17. Majdop S, Skomick Y, Avital S, Berkovich L (2018) Phospholipase D activation mediates growth and migration of colon cancer cells interacting with cancer-associated fibroblasts. Cell Mol Biol (Noisy-le-grand) 64(14):84–88
18. Rao J, Ashraf S, Tan W, van der Ven AT, Gee HY, Braun DA, Feher K, George SP, Esrameliaaakooshkhaoa A, Choi WJ, Jobst-Schwan T, Schneider R, Schmidt JM, Widmer E, Worejko JK, Hermel T, Scipachio D, Lovic S, Shih S, Daga A, Naray A, Shenoy M, Tse Y, Baid M, Helmchen U, Mir S, Berdell A, Kari JA, El Desoky S, Soliman NA, Bagga A, Manes S, Sairajpur MA, Lipton RF, Khurana S, Martins JC, Hildebrandt F (2017) Advinil acts upstream of phospholipase C-1 in steroid-resistant nephrotic syndrome. J Clin Invest 127(12):4257–4269
19. Kang DW, Choi KY, Min DS (2014) Functional regulation of phospholipase D expression in Cancer and Inflammation. J Biol Chem 289(33):22575–22582
20. Henkels KM, Bovin GP, Dudley ES, Berberich SJ, Gomez-Cambroner J (2013) Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model. Oncogene 32(49):5551–5562
21. Scott SA, Selvy PE, Buck JR, Cho HP, Criswell TL, Thomas AL, Armstrong MD, Antea GL, Lindsley CW, Brown HA (2009) Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 5(2):108–117
22. Lavieri RR, Scott SA, Selvy PE, Kim K, Jadhav S, Morrison RD, Daniels JS, Brown HA, Lindsley CW (2010) Design, synthesis, and biological evaluation of halogenated N-(4-oxo-1-phenyl-1,3,8-triazaziro-[4,3-de]can-8-y1)ethylbenzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor. J Med Chem 53(18):6706–6719
23. Su WJ, Chen Q, Frohman MA (2009) Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis. Future Oncology 5(9):1477–1486
24. Monovich L, Mugrave B, Quadros E, Toscano K, Tommasi R, LaVoie S, Liu E, Ou Z, Lasala D, Boyar W, Steed P (2007) Optimization of halopemide for phospholipase D2 inhibition. Bioorg Med Chem Lett 17(8):2310–2311
25. Brown HA, Thomas PG, Lindsley CW (2017) Targeting phospholipase D in cancer, infection and neurodegenerative disorders. Nat Rev Drug Discov 16(5):351–367
26. Chen Q, Hongu T, Sato T, Zhang Y, Wu W, Cavallo JA, van der Velden A, Tian HS, Di Paolo G, Nieswandt B, Kanahal Y, Frohman NA (2012) Key roles for the lipid signaling enzyme phospholipase D1 in the tumor microenvironment during tumor angiogenesis and metastasis. Sci Signal 5(249)
27. Belfiore L, Saunders DN, Ranson M, Thurecht JK, Storm G, Vine KL (2018) Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities. J Control Release 277:71–13
28. Caddeo C, Pucci L, Gabriele M, Carbone C, Fernandez-Busquets X, Valenti D, Pons R, Vassallo A, Fadda AM, Manconi M (2018) Stability, biocompatibility, and antioxidant activity of PRG-modified liposomes containing resveratrol. Int J Pharm 538(1–2):681–693
29. Ding Y, Cui W, Sun D, Wang GL, He Y, Meng S, Chen JH, Xie Y, Wang ZQ (2017) In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors. Drug Des Devel Ther 11:3105–3117
30. He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W (2019) Adapting liposomes for oral drug delivery. Acta Pharm Sin B 9(1):36–48
31. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65(1):36–48
32. Kouldefa S, Krotsgova PT, Masek J, Proczechka L, Lukac R, Miller AD, Neuzil J, Drisker DP (2017) In vivo study of doxorubicin-loaded cell-penetrating peptide-modified pH-sensitive liposomes: biocompatibility, bio-distribution, and pharmacodynamics in BALB/c nude mice bearing human breast tumors. Drug Des Devel Ther 11:3105–3117
33. F. Zeng, R.J. Ju, L. Liu, H.J. Xie, L.M. Mu, Y. Zhao, Y. Yan, Y.J. Hu, J.S. Wu, W.L. Zhang et al. (2019) A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS modified pH-sensitive liposomes: biocompatibility, bio-distribution, and antioxidant activity of PEG-modified liposomes containing resveratrol. Int J Pharm 538(1–2):681–693
36. Modi S, Xiang TX, Anderson BD (2012) Enhanced active liposomal loading of a poorly soluble ionicizable drug using supersaturated drug solutions. J Control Release 162(2):330–339

37. Shi J-F, Sun M-G, Li X-Y, Zhao Y, Ju R-J, Mu L-M, Yan Y, Li T-Z, Zeng F, Lu W-L (2015) A Combination of targeted sunitinib liposomes and targeted vinorelbine liposomes for treating invasive breast cancer. J Biomed Nanotechnol 11(9):1568–1582

38. Mallick A, More P, Ghosh S, Chippalkatti R, Chopade BA, Lahiri M, Basu S (2015) Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. Acta Appl Mater Interfaces 7(14):7584–7598

39. Vichai V, Kimkara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1(3):1112–1116

40. Ye Q, Kantonen S, Gomez-Cambronero J (2013) Serum deprivation confers the MDA-MB-231 breast cancer line with an EGF-REJAK3/PLD2 system that maximizes cancer cell invasion. J Mol Biol 425(4):755–766

41. Wang Z, Yu Y, Dai W, Cui J, Wu H, Yuan L, Zhang H, Wang X, Wang J, Zhang X, Zhang Q (2013) A specific peptide ligand-modified lipid nanoparticle carrier for the inhibition of tumor metastasis growth. Biomaterials 34(3):756–764

42. Rehman AU, Omran Z, Anton H, Mely Y, Akram S, Vandamme TF, Anton N (2018) Development of doxorubicin hydrochloride loaded pH-sensitive liposomes: Investigation on the impact of chemical nature of lipids and liposome composition on pH-sensitivity. Eur J Pharm Biopharm 133:331–338

43. Ma S, Li M, Liu N, Li Y, Li Z, Yang Y, Yu F, Hu X, Liu C, Mei X (2017) Vinorelbine liposomes with smaller particle size have stronger diffusion ability in tumor and improve tumor accumulation of vinorelbine significantly. Oncotarget 8(5):87276–87291

44. Andar AU, Hood RR, Vreeland WN, Devoe DL, Swaan PW (2014) Microfluidic preparation of liposomes to determine particle size influence on cellular uptake mechanisms. Pharm Res 31(2):401–413

45. Chono S, Tauchi Y, Morimoto K (2006) Influence of particle size on the distributions of liposomes to atherosclerotic lesions in mice. Drug Dev Ind Pharm 32(1):125–135

46. Chu KS, Hasan W, Rawal S, Walsh MD, Luft JC, Cannon TG, Liu C, Mei X (2017) Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 252:262–275

47. Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 91:3–6

48. T.A.J. Wilhelm S, Dai Q, et al., Analysis of nanoparticle delivery to tumours, Nat Rev Mater 1(5) (2016) 16014.

49. Soenen SJ, Brisson AR, De Cuyper M (2009) Addressing the problem of pharmacokinetics of docetaxel delivered via nanoparticles of different sizes and shapes in mice bearing SKOV-3 human ovarian carcinoma xenograft. Nanomedicine 9(5):686–693

50. Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 91:3–6

51. Kulkarni SA, Feng SS (2013) Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharm Res 30(10):2512–2522

52. Salatin S, Maleki Dojaz S, Yari Khorsroushahi A (2015) Effect of the surface modification, size, and shape on cellular uptake of nanoparticles. Cell Biol Int 39(8):881–890

53. Zheng M, Yu J (2016) The effect of particle shape and size on cellular uptake. Drug Deliv Transl Res 6(1):67–72

54. Zhang M, Altuwaij S, Yeh S (2004) RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness. Oncogene 23(17):3080–3088

55. Zhong ZF, Tan W, Tian K, Yu H, Qiang WA, Wang YT (2017) Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro. Oncof Rep 37(4):2016–2024

56. Bandyopadhyay A, Wang L, Aguin J, Tang Y, Lin S, Yeh IT, De K, Sun LZ (2010) Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 5(6):e10365

57. Crispin PL, Uzzo RG, Golovine K, Makarov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM (2007) Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. Prostate 67(8):582–590

58. Wirtz D, Konstantopoulos K, Pearson PC (2011) The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat Rev Cancer 11(7):512–522